Scarica l'app Stockscreener
78.92
6.22%
4.62
Dopo l'orario di chiusura:
78.70
-0.22
-0.28%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$74.30
Aprire:
$74.32
Volume 24 ore:
6.73M
Relative Volume:
1.85
Capitalizzazione di mercato:
$30.95B
Reddito:
$4.30B
Utile/perdita netta:
$571.50M
Rapporto P/E:
54.81
EPS:
1.44
Flusso di cassa netto:
$570.80M
1 W Prestazione:
+3.33%
1M Prestazione:
-0.45%
6M Prestazione:
-8.22%
1 anno Prestazione:
+9.07%
Intervallo 1D:
$74.00
$79.51
Intervallo di 1 settimana:
$73.47
$79.51
Portata 52W:
$57.52
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Confronta DXCM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
78.92 | 29.14B | 4.30B | 571.50M | 570.80M | 1.44 |
|
ABT
Abbott Laboratories
|
132.18 | 228.80B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
107.53 | 158.04B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
388.56 | 149.08B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.25 | 119.71B | 34.20B | 4.69B | 5.30B | 3.63 |
|
EW
Edwards Lifesciences Corp
|
81.22 | 48.01B | 5.69B | 1.41B | 577.90M | 6.95 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-21 | Iniziato | Argus | Buy |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
Transcript : DexCom, Inc. Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-03-2025 02 - MarketScreener
What data driven models say about DexCom Inc.’s future2025 Price Momentum & Reliable Entry Point Trade Alerts - Newser
What momentum shifts mean for DexCom Inc.2025 Dividend Review & Short-Term High Return Ideas - Newser
Applying Wyckoff theory to DexCom Inc. stock2025 Market Overview & Verified Swing Trading Watchlists - Newser
Published on: 2025-09-03 08:54:41 - Newser
How to recover losses in DexCom Inc. stockWeekly Market Report & Comprehensive Market Scan Reports - Newser
Analyzing DexCom Inc. with risk reward ratio charts2025 Short Interest & High Return Trade Guides - Newser
Will DexCom's (DXCM) Latest Investor Update Hint at a Shifting Innovation Strategy? - simplywall.st
Analyzing drawdowns of DexCom Inc. with statistical toolsTrade Risk Assessment & High Conviction Buy Zone Alerts - Newser
Custom watchlist performance reports with DexCom Inc.July 2025 Market Mood & Scalable Portfolio Growth Ideas - Newser
Tools to assess DexCom Inc.’s risk profileWeekly Profit Summary & Safe Entry Trade Reports - Newser
Market reaction to DexCom Inc.’s recent newsJuly 2025 Weekly Recap & Technical Pattern Based Buy Signals - Newser
Understanding DexCom Inc.’s price movementJuly 2025 Breakouts & Expert-Curated Trade Recommendations - Newser
What candlestick patterns are forming on DexCom Inc.2025 Institutional Moves & Weekly Breakout Watchlists - Newser
Exit strategy if you’re trapped in DexCom Inc.July 2025 Analyst Calls & Daily Stock Trend Watchlist - Newser
Using data filters to optimize entry into DexCom Inc.July 2025 Institutional & Consistent Profit Alerts - Newser
Ranking DexCom Inc. among high performing stocks via toolsRisk Management & Consistent Profit Alerts - Newser
Custom watchlist performance reports with DexCom IncMarket Performance Report & Fast Moving Stock Watchlists - Newser
DexCom Faces Evaluation Adjustment Amid Strong Financial Performance and Quality Concerns - Markets Mojo
Stock Analysis | Dexcom OutlookWeak Technicals and Mixed Analyst Sentiment - AInvest
Should you hold or exit DexCom Inc. nowTrade Analysis Summary & Free Fast Gain Swing Trade Alerts - Newser
Dexcom Trails Medtronic in Diabetes Tech Race as $330M Volume Marks 343rd Market Rank - AInvest
What to do if you’re stuck in DexCom Inc.Trade Risk Summary & Free High Return Stock Watch Alerts - Newser
DexCom Loses EU Patent For Glucose Sensor Design - Law360
Using RSI to spot recovery in DexCom Inc.Index Update & Proven Capital Preservation Methods - Newser
Is DexCom Inc. trending in predictive chart modelsJuly 2025 Spike Watch & Weekly Setup with High ROI Potential - Newser
Will DexCom Inc. benefit from government policy2025 Market Overview & Community Trade Idea Sharing - khodrobank.com
How to use a screener to detect DexCom Inc. breakoutsJuly 2025 Analyst Calls & Technical Entry and Exit Alerts - Newser
What is DexCom Inc.’s TAM (Total Addressable Market)Dollar Strength & High Accuracy Trade Alerts - khodrobank.com
Can DexCom Inc. benefit from deglobalization2025 Stock Rankings & Fast Entry High Yield Stock Tips - khodrobank.com
Using R and stats models for DexCom Inc. forecastingWeekly Earnings Recap & Proven Capital Preservation Tips - Newser
Can DexCom Inc. Bounce Back From Weekly Low getLinesFromResByArray error: size == 0 - thegnnews.com
Can trapped investors hope for a rebound in DexCom Inc.Weekly Risk Report & AI Powered Market Entry Strategies - Newser
Will DexCom Inc. continue its uptrendJuly 2025 Macro Moves & High Return Trade Opportunity Guides - Newser
Short interest data insights for DexCom Inc.July 2025 PreEarnings & Verified Swing Trading Watchlists - Newser
Marvell Technology, eBay, And DexCom Are Among Top 10 Large Cap Losers Last Week (August 25-August 29): Are The Others In Your Portfolio? - Benzinga
DexCom P/E Ratio Analysis: Undervalued or Overvalued? - AInvest
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.09%
0.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):